We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type |
---|---|---|---|
Bristol Myers Squibb Co | NYSE:BMY | NYSE | Common Stock |
Price Change | % Change | Share Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|
-0.35 | -0.78% | 44.71 | 45.715 | 44.525 | 45.21 | 13,228,204 | 21:15:04 |
By Philip Waller
LONDON--Shares in Beximco Pharmaceuticals Ltd (BXP.LN) rose 7.4% on Monday after it said U.S. regulators have given it the go-ahead to market its extended-release Metformin tablets for diabetes control.
The generic drug manufacturer said the U.S. Food & Drug Administration has approved 500 milligram and 750 mg versions of the Metformin Hydrochloride tablets.
The tablets are the generic equivalent to Bristol-Myers Squibb's (BMY) Glucophage XR tablets in the same dosages.
Annual sales for Glucophage XR in the U.S. were $918 million for the year ended Oct. 31, according to IMS data.
At 0848 GMT, shares in Beximco were up 3.5 pence at 51 pence.
-Write to Philip Waller at philip.waller@wsj.com
(END) Dow Jones Newswires
December 19, 2016 04:13 ET (09:13 GMT)
Copyright (c) 2016 Dow Jones & Company, Inc.
1 Year Bristol Myers Squibb Chart |
1 Month Bristol Myers Squibb Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions